Literature DB >> 34581899

Upfront metastasis‑directed therapy in oligorecurrent prostate cancer does not decrease the time from initiation of androgen deprivation therapy to castration resistance: in response to Onal's letter to the editor.

L Triggiani1, D Tomasini2, R Mazzola3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34581899     DOI： 10.1007/s12032-021-01583-x

Source DB:  PubMed          Journal:  Med Oncol        ISSN： 1357-0560            Impact factor:   3.064


× No keyword cloud information.
  3 in total

1.  Metastasis-directed Therapy (SBRT) Guided by PET-CT 18F-CHOLINE Versus PET-CT 68Ga-PSMA in Castration-sensitive Oligorecurrent Prostate Cancer: A Comparative Analysis of Effectiveness.

Authors:  Rosario Mazzola; Giulio Francolini; Luca Triggiani; Giuseppe Napoli; Francesco Cuccia; Luca Nicosia; Lorenzo Livi; Stefano Maria Magrini; Matteo Salgarello; Filippo Alongi
Journal:  Clin Genitourin Cancer       Date:  2020-08-06       Impact factor: 2.872

2.  Upfront metastasis‑directed therapy in oligorecurrent prostate cancer does not decrease the time from initiation of androgen deprivation therapy to castration resistance: in regard to Triggiani et al.

Authors:  Cem Onal; Ezgi Oymak; Ozan Cem Guler
Journal:  Med Oncol       Date:  2021-06-11       Impact factor: 3.064

3.  Upfront metastasis-directed therapy in oligorecurrent prostate cancer does not decrease the time from initiation of androgen deprivation therapy to castration resistance.

Authors:  Luca Triggiani; Rosario Mazzola; Davide Tomasini; Alessio Bruni; Giulia Alicino; Fabio Matrone; Roberto Bortolus; Giulio Francolini; Beatrice Detti; Alessandro Magli; Marco Lorenzo Bonù; Gianluca Ingrosso; Andrea Lancia; Fabio Trippa; Ernesto Maranzano; Ciro Franzese; Paolo Ghirardelli; Vittorio Vavassori; Marta Scorsetti; Filippo Alongi; Stefano Maria Magrini
Journal:  Med Oncol       Date:  2021-05-18       Impact factor: 3.064
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.